SIBRAFIBAN VS ASPIRIN PROTECTION FROM ISCHEMIC HEART EVENTS

Symphony试验-西布非班与阿司匹林对急性冠状动脉综合征后缺血性心脏事件的最大保护作用是一项多中心药物试验，比较西布非班（一种口服血小板糖蛋白IIb/IIIa拮抗剂）与阿司匹林预防急性冠状动脉综合征后继发性血管事件的疗效。该研究现已结束招募，下一阶段是III期双盲研究。

The Symphony Trial- Sibrafiban vs. aspirin to yield maximum protection from ischemic heart events post acute coronary syndromes is a multi-center drug trial comparing the efficacy of Sibrafiban, an oral platelet glycoprotein IIb/IIIa antagonist to aspirin as therapy for the prevention of secondary vascular events in patients after an acute coronary syndrome. This study is now closed to recruitment and the next phase is a phase III double blind study.